David Young, the President of Research & Development at Processa Pharmaceuticals, completed a stock transaction on January 1, 2024. Young executed a sale of 518 shares of common stock at a price of $2.79 per share, resulting in a total market value of $1,445.22. This transaction was part of a disposal activity that was described as a payment of exercise price or tax liability by delivering or withholding securities. Following this transaction, Young's direct holdings in the company amounted to 80,544 shares. Additionally, Young has indirect beneficial ownership of 60,315 shares through various entities, including the Young-Plaisance Revocable Trust, Family Entities, and CorLyst, LLC. The transaction was reported as completed on the same day.

David Young, the President of Research & Development at Processa Pharmaceuticals, completed a stock transaction on January 1, 2024. Young executed a sale of 518 shares of common stock at a price of $2.79 per share, resulting in a total market value of $1,445.22. This transaction was part of a disposal activity that was described as a payment of exercise price or tax liability by delivering or withholding securities. Following this transaction, Young's direct holdings in the company amounted to 80,544 shares. Additionally, Young has indirect beneficial ownership of 60,315 shares through various entities, including the Young-Plaisance Revocable Trust, Family Entities, and CorLyst, LLC. The transaction was reported as completed on the same day.